



Physician:

## Laboratory Report Online Version

Report Date: 17.07.2021

**Patient Name: SAMPLE REPORT ONLY**

Gender: Female  
Date of Birth: 01.01.2021  
Nationality:  
Your ID:

Test Request Code:  
Sample ID:  
Patient IDNo:

Sampling Date / Time: 08.07.2021 / 00:00  
Receipt Date / Time: 10.07.2021 / 00:00

Remarks:

Insurance:

Analysis	Result	Flag	Units	Reference Range
----------	--------	------	-------	-----------------

### Exclusion of Metabolic Diseases (Filter card)

Week of gestation	38
Newborn screening*	normal

No sign of the following disorders:  
Amino Acid related disorders such as: Phenylketonuria (PKU),  
Hyperphenylalaninaemia, Maple syrup disease etc.  
Fatty acid oxidation disorders and other disorders recognized in the  
acylcarnitine spectrum: e.g. MCAD, LCAD, VLCAD  
Other screened disorders: e.g. Hypothyreosis, AGS, Biotinidase deficiency,  
G6PDH Deficiency, Cystic Fibrosis, SCID, Hemoglobinopathies  
(HbS, HbC, HbD, HbE, HbH/HbBarts, HbO, HbLepore, HbG, beta-Thalassemia)

Methods: MS-MS, FIA, Photometry, Capillary Electrophoresis

Please note that the best time of collecting blood for NBS is 36-72 hours after birth.

Amino Acids (PKU etc.)*	normal	quantitative	normal
Acylcarnitines (Fatty acids)*	normal	quantitative	normal
TSH (Hypothyreodism)*	normal	quantitative	normal
17a-OH-Progesterone (AGS)*	normal	quantitative	normal
Galactose (Galactosemia)*	normal	quantitative	normal

The classical form of Galactosemia can be excluded.  
However, mild forms e.g. DUARTE, might not be recognized.

### This report was technically validated

Note:  
Our reference values are adjusted to age and gender.  
Daily internal Quality Control within the required range  
(according to Rili-BÄK).  
External Quality Control available on request.

\* non-accredited parameter

\* This parameter is affected by Biotin intake of >5 mg  
(RDI = 0.03mg)

\* This investigation has been performed in a collaborating  
accredited laboratory (Germany).

Techn. Validation by  
Med. Technologist  
(Supervisor of  
the Department)

Dr. Nehmat ElBanna  
Specialist  
Clinical Pathology  
(DHA- 84548-001)

PD Dr. med. habil. M. Jaksch  
Associate Professor  
Medical Director  
(DHA-LS-240710)



This report has been printed through Imed-Online-Reporting-System and therefore does not carry a signature.



Physician:

## Laboratory Report Online Version

Report Date: 17.07.2021

**Patient Name: SAMPLE REPORT ONLY**

Gender: Female  
Date of Birth: 01.01.2021  
Nationality:  
Your ID:

Test Request Code:  
Sample ID:  
Patient IDNo:

Sampling Date / Time: 08.07.2021 / 00:00  
Receipt Date / Time: 10.07.2021 / 00:00

Remarks:

Insurance:

Analysis	Result	Flag	Units	Reference Range
----------	--------	------	-------	-----------------

### Exclusion of Metabolic Diseases (Filter card), Continuation

<b>Biotinidase (Biot.deficiency)*</b>	normal		quantitative	normal
<b>Glucose-6-PDH*</b>	normal		quantitative	normal
<b>Immunoreactive Trypsin*</b>	normal		quantitative	normal
<b>SCID Screening*</b>	normal		qualitative	normal

No evidence of Severe Combined Immunodeficiency.

<b>Hemoglobin Screening*</b>	normal		quantitative	normal
------------------------------	--------	--	--------------	--------

### This report was technically validated

Note:  
Our reference values are adjusted to age and gender.  
Daily internal Quality Control within the required range  
(according to Rili-BÄK).  
External Quality Control available on request.

^ non-accredited parameter

\*This parameter is affected by Biotin intake of >5 mg  
(RDI = 0.03mg)

\* This investigation has been performed in a collaborating  
accredited laboratory (Germany).

Techn. Validation by  
**Med. Technologist**  
(Supervisor of  
the Department)

**Dr. Nehmat ElBanna**  
Specialist  
Clinical Pathology  
(DHA- 84548-001)

**PD Dr. med. habil. M. Jaksch**  
Associate Professor  
Medical Director  
(DHA-LS-240710)



This report has been printed through Imed-Online-Reporting-System and therefore does not carry a signature.